← Back to Analyst Consensus 
TNGX Buy
Tango Therapeutics, Inc.
Current Price —
Implied Upside —
Analysts 18
30-Day Momentum
▲ 1 upgrades / ▼ 0 downgrades / 0 reiterations from 1 firms
Next Earnings
Nov 10, 2026 (14 days)
Rating Timeline
| Date ▼ | Firm | Action | From → To Rating | Price Target | Firm Rating |
|---|---|---|---|---|---|
| Oct 16, 2026 | William Blair | initiate | — → Outperform | — | 48% |
| Aug 18, 2026 | HC Wainwright & Co. | maintain | Buy → Buy | — | 44% |
| Aug 12, 2026 | Guggenheim | maintain | Buy → Buy | — | 52% |
| Jul 17, 2026 | Mizuho | maintain | Outperform → Outperform | — | 52% |
| Jul 15, 2026 | JP Morgan | initiate | — → Overweight | — | 55% |
| Jun 29, 2026 | Canaccord Genuity | maintain | Buy → Buy | — | 48% |
| Jun 26, 2026 | Jefferies | upgrade | Hold → Buy | — | 52% |
| Jun 11, 2026 | Canaccord Genuity | maintain | Buy → Buy | — | 48% |
| Jun 9, 2026 | HC Wainwright & Co. | maintain | Buy → Buy | — | 44% |
| Jun 9, 2026 | Canaccord Genuity | maintain | Buy → Buy | — | 48% |
| Jun 8, 2026 | Leerink Partners | maintain | Outperform → Outperform | — | 51% |
| May 15, 2026 | Mizuho | maintain | Outperform → Outperform | — | 52% |
| May 15, 2026 | Piper Sandler | downgrade | Overweight → Neutral | — | 54% |
| May 14, 2026 | Jefferies | downgrade | Buy → Hold | — | 52% |
| May 14, 2026 | Leerink Partners | maintain | Outperform → Outperform | — | 51% |
| May 14, 2026 | Wedbush | maintain | Outperform → Outperform | — | 58% |
| Apr 27, 2026 | Stifel | maintain | Buy → Buy | — | 54% |
| Apr 2, 2026 | Canaccord Genuity | initiate | — → Buy | — | 48% |
| Mar 11, 2026 | Mizuho | maintain | Outperform → Outperform | — | 52% |
| Mar 9, 2026 | Stifel | maintain | Buy → Buy | — | 54% |
| Mar 6, 2026 | Wedbush | maintain | Outperform → Outperform | — | 58% |
| Mar 6, 2026 | Guggenheim | maintain | Buy → Buy | — | 52% |
| Mar 6, 2026 | HC Wainwright & Co. | maintain | Buy → Buy | — | 44% |
| Feb 23, 2026 | Mizuho | initiate | — → Outperform | $19 | 52% |
| Feb 6, 2026 | Guggenheim | maintain | Buy → Buy | $18 | 52% |
| Jan 16, 2026 | Piper Sandler | maintain | Overweight → Overweight | $14 | 54% |
| Dec 4, 2025 | Stifel | initiate | — → Buy | $15 | 54% |
| Nov 18, 2025 | Wolfe Research | initiate | — → Peer Perform | $0 | 54% |
| Nov 18, 2025 | B. Riley Securities | maintain | Buy → Buy | $14 | 54% |
| Oct 24, 2025 | Guggenheim | maintain | Buy → Buy | $12 | 52% |
| Aug 19, 2025 | Piper Sandler | initiate | — → Overweight | $11 | 54% |
| Aug 6, 2025 | Guggenheim | maintain | Buy → Buy | $10 | 52% |
| Apr 14, 2025 | HC Wainwright & Co. | reiterate | Buy → Buy | $13 | 44% |
| Dec 5, 2024 | Cantor Fitzgerald | reiterate | Overweight → Overweight | $0 | 50% |
| Nov 11, 2024 | B. Riley Securities | maintain | Buy → Buy | $8 | 54% |
| Nov 8, 2024 | HC Wainwright & Co. | reiterate | Buy → Buy | $13 | 44% |
| Nov 7, 2024 | Guggenheim | maintain | Buy → Buy | $8 | 52% |
| Oct 28, 2024 | HC Wainwright & Co. | reiterate | Buy → Buy | $13 | 44% |
| Sep 10, 2024 | HC Wainwright & Co. | reiterate | Buy → Buy | $13 | 44% |
| Aug 8, 2024 | Wedbush | maintain | Outperform → Outperform | $13 | 58% |
| Jul 17, 2024 | Jefferies | initiate | — → Buy | $19 | 52% |
| Jul 9, 2024 | Cantor Fitzgerald | reiterate | — → Overweight | $0 | 50% |
| Jul 9, 2024 | HC Wainwright & Co. | reiterate | Buy → Buy | $13 | 44% |
| May 28, 2024 | HC Wainwright & Co. | maintain | Buy → Buy | $13 | 44% |
| May 24, 2024 | Guggenheim | maintain | Buy → Buy | $14 | 52% |
| May 24, 2024 | Barclays | maintain | Overweight → Overweight | $13 | 53% |
| May 23, 2024 | Wedbush | maintain | Outperform → Outperform | $11 | 58% |
| May 9, 2024 | HC Wainwright & Co. | reiterate | Buy → Buy | $17 | 44% |
| Apr 4, 2024 | Cantor Fitzgerald | initiate | — → Overweight | $0 | 50% |
| Mar 20, 2024 | HC Wainwright & Co. | maintain | Buy → Buy | $17 | 44% |
Price Target Trend
Jul 11, 2026 Oct 26, 2026
EPS Estimates
0y —
+1q —
0q —
+1y —
Cross-Platform Signals
No cross-platform signals in the last 90 days